Brokerages forecast that Ascendis Pharma A/S (NASDAQ:ASND) will report sales of $660,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $20,000.00 and the highest is $1.74 million. Ascendis Pharma A/S posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 2,100%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 29th.

On average, analysts expect that Ascendis Pharma A/S will report full year sales of $34.03 million for the current fiscal year, with estimates ranging from $90,000.00 to $128.00 million. For the next fiscal year, analysts forecast that the business will post sales of $29.56 million, with estimates ranging from $90,000.00 to $114.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.30. The business had revenue of $12.00 million for the quarter. Ascendis Pharma A/S had a negative return on equity of 40.86% and a negative net margin of 1,275.08%.

Several analysts have recently issued reports on the company. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Friday. Wedbush reiterated a “buy” rating and issued a $219.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, April 8th. Canaccord Genuity raised their price target on Ascendis Pharma A/S from $132.00 to $133.00 and gave the company a “buy” rating in a research note on Friday, April 5th. Credit Suisse Group cut their price target on Ascendis Pharma A/S from $151.00 to $139.00 and set an “outperform” rating on the stock in a research note on Friday, March 29th. Finally, Evercore ISI assumed coverage on Ascendis Pharma A/S in a research note on Monday, March 25th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Ascendis Pharma A/S currently has an average rating of “Buy” and an average target price of $135.56.

A number of institutional investors have recently bought and sold shares of ASND. BlackRock Inc. grew its position in Ascendis Pharma A/S by 5.1% in the third quarter. BlackRock Inc. now owns 460,961 shares of the biotechnology company’s stock worth $32,663,000 after acquiring an additional 22,172 shares during the period. Morgan Stanley boosted its holdings in Ascendis Pharma A/S by 53.6% in the 3rd quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock valued at $3,338,000 after purchasing an additional 16,434 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in Ascendis Pharma A/S in the 4th quarter valued at approximately $25,000. SG Americas Securities LLC purchased a new stake in Ascendis Pharma A/S in the 4th quarter valued at approximately $116,000. Finally, TD Asset Management Inc. boosted its holdings in Ascendis Pharma A/S by 15.8% in the 4th quarter. TD Asset Management Inc. now owns 76,672 shares of the biotechnology company’s stock valued at $4,804,000 after purchasing an additional 10,436 shares in the last quarter. Institutional investors own 94.86% of the company’s stock.

Shares of NASDAQ ASND traded up $2.91 during mid-day trading on Tuesday, hitting $120.28. The company had a trading volume of 261,000 shares, compared to its average volume of 362,421. The stock has a market cap of $5.11 billion, a P/E ratio of -32.16 and a beta of 0.94. Ascendis Pharma A/S has a 1-year low of $53.21 and a 1-year high of $131.76.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.